Zenith Healthcare Limited

zenithhealthcare.com

Zenith Healthcare Limited (ZHL) is a listed public Limited Company managed by a Professional Chartered Accountant since 20 years. Situated nearby leading pharmaceutical hub of India in Ahmedabad, Gujarat, INDIA. Zenith Healthcare Limited is one of India’s leading pharmaceutical companies with a strong presence in the country’s domestic formulations market.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MOLECULIN ANNOUNCES NEW ANTIVIRAL DRUG CANDIDATES DEMONSTRATE IN VITRO ACTIVITY AGAINST HIV

Moleculin Biotech, Inc | October 07, 2020

news image

Moleculin Biotech, Inc., (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting significant unmet needs in the treatment of tumors and viruses, announced preliminary new findings from its research collaboration with the Rega Institute in Leuven, Belgium, that demonstrate its drug candidates, WP1096 and WP1097, are showing significant in vitro activity in a range of infectious diseases. In addition to activity against SARS-CoV...

Read More

Views and Analysis

ENTERIS BIOPHARMA PUBLISHES WHITE PAPER EXAMINING FACTORS TO CONSIDER WHILE EVALUATING ORAL ADMINISTRATION OF PEPTIDES

Enteris BioPharma | September 13, 2022

news image

Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation announced the publication of a new white paper in Drug Development & Delivery entitled, "Key Considerations in Oral Delivery of Peptides – Factors to Consider While Evaluating Oral Administration." The paper, authored by John Vrettos, PhD, Director of Formulation Developmen...

Read More

VIEWS AND ANALYSIS, PHARMACY MARKET

ALTRO PHARMACEUTICALS TEAMS UP WITH LSPEDIA TO PROVIDE CUTTING-EDGE TECHNOLOGY FOR FDA DSCSA COMPLIANCE

PRNewswire | July 31, 2023

news image

LSPedia, a leading SaaS provider specializing in product traceability solutions for the pharmaceutical industry, has partnered with Altro Pharmaceuticals, enabling Altro customers to easily comply with the Drug Supply Chain Security Act (DSCSA) ahead of the FDA's final deadline on November 27, 2023. Altro provides expertise and services to pharmaceutical manufacturers and wholesale distributors, helping them expand their businesses, streamline supply chain operations, increa...

Read More

OCUPHIRE PHARMA ANNOUNCES IN-LICENSE OF PHASE 2 ORAL SMALL MOLECULE DRUG CANDIDATE FOR DIABETIC RETINOPATHY

Business Wire | January 22, 2020

news image

Ocuphire Pharma, Inc., a clinical-stage pharmaceutical company focused on the development and commercialization of therapies to treat patients with a variety of ophthalmic disorders, today announced that it has entered into an agreement with Apexian Pharmaceuticals, Inc., granting Ocuphire an exclusive worldwide sublicense to Apexian’s Ref-1 Inhibitor program, including its lead drug candidate APX3330, for all ophthalmic and diabetic indications. APX3330 is a first-in-class, orally-adminis...

Read More
news image

MOLECULIN ANNOUNCES NEW ANTIVIRAL DRUG CANDIDATES DEMONSTRATE IN VITRO ACTIVITY AGAINST HIV

Moleculin Biotech, Inc | October 07, 2020

Moleculin Biotech, Inc., (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting significant unmet needs in the treatment of tumors and viruses, announced preliminary new findings from its research collaboration with the Rega Institute in Leuven, Belgium, that demonstrate its drug candidates, WP1096 and WP1097, are showing significant in vitro activity in a range of infectious diseases. In addition to activity against SARS-CoV...

Read More
news image

Views and Analysis

ENTERIS BIOPHARMA PUBLISHES WHITE PAPER EXAMINING FACTORS TO CONSIDER WHILE EVALUATING ORAL ADMINISTRATION OF PEPTIDES

Enteris BioPharma | September 13, 2022

Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation announced the publication of a new white paper in Drug Development & Delivery entitled, "Key Considerations in Oral Delivery of Peptides – Factors to Consider While Evaluating Oral Administration." The paper, authored by John Vrettos, PhD, Director of Formulation Developmen...

Read More
news image

VIEWS AND ANALYSIS, PHARMACY MARKET

ALTRO PHARMACEUTICALS TEAMS UP WITH LSPEDIA TO PROVIDE CUTTING-EDGE TECHNOLOGY FOR FDA DSCSA COMPLIANCE

PRNewswire | July 31, 2023

LSPedia, a leading SaaS provider specializing in product traceability solutions for the pharmaceutical industry, has partnered with Altro Pharmaceuticals, enabling Altro customers to easily comply with the Drug Supply Chain Security Act (DSCSA) ahead of the FDA's final deadline on November 27, 2023. Altro provides expertise and services to pharmaceutical manufacturers and wholesale distributors, helping them expand their businesses, streamline supply chain operations, increa...

Read More
news image

OCUPHIRE PHARMA ANNOUNCES IN-LICENSE OF PHASE 2 ORAL SMALL MOLECULE DRUG CANDIDATE FOR DIABETIC RETINOPATHY

Business Wire | January 22, 2020

Ocuphire Pharma, Inc., a clinical-stage pharmaceutical company focused on the development and commercialization of therapies to treat patients with a variety of ophthalmic disorders, today announced that it has entered into an agreement with Apexian Pharmaceuticals, Inc., granting Ocuphire an exclusive worldwide sublicense to Apexian’s Ref-1 Inhibitor program, including its lead drug candidate APX3330, for all ophthalmic and diabetic indications. APX3330 is a first-in-class, orally-adminis...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us